Dengue Controlled Human Infection Model in Dhaka, Bangladesh

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

December 11, 2021

Primary Completion Date

November 20, 2023

Study Completion Date

July 31, 2025

Conditions
Dengue
Interventions
BIOLOGICAL

TV005

The TV005 admixture is comprised of four monovalent dengue vaccine candidates representing each of the four DENV serotypes: rDEN1Δ30, rDEN2/4Δ30(ME), rDEN3Δ30/31, and rDEN4Δ30.

BIOLOGICAL

rDEN2Δ30-7169 attenuated virus strain

based on a cDNA derived DENV-2 virus (strain Tonga/74) in which the 3´ UTR of DENV-2 contains a 30 (nt) deletion (nt 173 - 143) homologous to the ∆30 deletion in the 3´ UTR of rDEN4Δ30 (named Δ30 for consistency). A plasmid was constructed to encode the entire genome of DENV-2 Tonga/74. The cDNA of the 3´ UTR of DENV-2 Tonga/74 was then modified to introduce a 31-nucleotide deletion homologous to the DEN4Δ30 deletion (∆30). Genome-length, capped, RNA transcripts were synthesized from the plasmid p2Δ30-7169 and purified

Trial Locations (1)

Unknown

Icddr,B, Dhaka

All Listed Sponsors
collaborator

International Centre for Diarrhoeal Disease Research, Bangladesh

OTHER

lead

Beth Kirkpatrick

OTHER